Recent articles
The 1 Stock I'd Buy Right Now
The genetic testing industry is still in its infancy, but this leader is comfortably profitable and growing at a healthy clip.
Can Amyris Succeed With Its Latest Turnaround?
The company hopes new products in development and a reshuffled debt portfolio can deliver long-awaited growth and profits. Investors have heard that before.
Here's Why Beyond Meat Fell as Much as 10.8% Today
Mr. Market wields a sledgehammer and takes no prisoners. He may be right about today's move.
Here's Why BioCryst Pharmaceuticals Collapsed Today
This is a case study of when a successful phase 3 trial isn't successful enough.
These 3 Small-Cap Healthcare Stocks Reported Big Updates This Month
Axsome Therapeutics, Flexion Therapeutics, and UroGen Pharma gave investors reasons for excitement.
3 Stocks to Buy Ahead of the Next Market Crash
Whether it's imminent or not, it's always a good idea to be prepared.
Pennsylvania's Nuclear Fumble Will Be a Costly Climate Mistake
The state legislature isn't properly valuing the power source's role in combating climate change. Will Exelon's tried-and-true strategy force a last-minute deal?
Investors Are Right to Worry About Puma Biotechnology
A surprising number of patients discontinued treatment with the company's sole drug product in the first quarter of 2019.
Here's Why Ironwood Pharmaceuticals Rose as Much as 12% Today
An SEC filing shows an activist investor is building a sizable position in the company.
Here's Why Iovance Biotherapeutics Soared Today
The company's promising immunotherapy approach delivered impressive data in multiple studies.
Here's Why Agilent Tumbled Today
The lab equipment and services provider reduced full-year fiscal 2019 revenue guidance. Is today's tumble just a big overreaction?
Myriad Genetics Reduced 2019 Guidance, but Is It Really So Bad?
The genetic testing pioneer lost $500 million in value after reporting fiscal Q3 operating results.
Green Plains Wrestles With Weak Ethanol Margins in Q1
Management has a plan to make the company one of the lowest-cost producers in the industry. Will it work?
Here's Why Athersys Rose as Much as 15.2% Today
The FDA has given the company's lead drug platform a potential leg up in development.
Here's Why Solid Biosciences Fell as Much as 40.9% Today
The gene therapy developer appears to be struggling to find a safe and effective dose of its experimental Duchenne muscular dystrophy treatment.
3 Top Value Stocks to Buy Right Now
Don't let a historically expensive stock market get you down. Give these three bargain stocks a look.
Here's Why Generic-Drug Manufacturers Were Down Monday
Forty-four states have brought a lawsuit against the industry.
Aqua America Readies for Peoples Acquisition to Close in Mid-2019
The water utility announced a solid Q1 performance and reiterated full-year guidance, but the real excitement lies in the pending merger with Peoples.
Franco-Nevada Gets Back on Track With Record Q1 Results
The all-important Cobre Panama project remains on track, but it had nothing to do with a strong start to 2019.
Wall Street Rains on Albemarle's Solid Q1 Performance
The lithium segment struggled to overcome weather events in Chile, but the company's more mature businesses helped to partially offset the headwind.